前沿速览058期| CAR-T治B淋 前沿览新知
01
CD19 CAR-T细胞治疗中枢神经系统淋巴瘤的失败模式、危险因素及应对策略
Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma
第一作者：Kaulen LD
J Hematol Oncol (IF=40.4). 2026 Jan 14;19(1):2.
全文网址：https://link.springer.com/article/10.1186/s13045-025-01761-8
02
大B细胞淋巴瘤CAR-T细胞治疗失败后Post-CAR预后指数的多中心真实世界评估
Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure
第一作者：Farina M
J Hematol Oncol (IF=40.4). 2026 Jan 8;19(1):4.
全文网址：https://link.springer.com/article/10.1186/s13045-025-01771-6
03
Axicabtagene ciloleucel联合利妥昔单抗治疗难治性大B细胞淋巴瘤：一项II期单臂ZUMA-14研究
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial
第一作者：Strati P
Nat Cancer (IF=28.5). 2026 Jan 5.
全文网址：https://www.nature.com/articles/s43018-025-01102-1
04
CAR-T细胞回输时段对大B细胞淋巴瘤患者预后的影响
Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma
第一作者：Luan D
Blood (IF=23.1). 2025 Dec 23:blood.2025031476.
全文网址：https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2025031476/557451/Time-of-Day-of-CAR-T-Cell-Infusion-and-Outcomes-in?redirectedFrom=fulltext
05
CAR-T细胞治疗血液系统恶性肿瘤的疗效与安全性：基于临床试验比例的系统评价与荟萃分析
Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials
第一作者：Filippatos C
Am J Hematol (IF=10.3). 2026 Jan 9.
全文网址：https://onlinelibrary.wiley.com/doi/10.1002/ajh.70201
06
Zamtocabtagene Autoleucel治疗复发/难治性B细胞非霍奇金淋巴瘤：一项CD20/19双靶点CAR-T细胞I期试验的五年随访结局
Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial
第一作者：Balke-Want H
Blood Adv (IF=7.1). 2026 Jan 9:bloodadvances.2025018073.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025018073/565941/Zamtocabtagene-Autoleucel-in-Relapsed-refractory-B
07
不适合移植的大B细胞淋巴瘤患者接受二线Axi-cel治疗后的健康相关生活质量
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma
第一作者：Charton E
Blood Adv (IF=7.1). 2026 Jan 9:bloodadvances.2025018057.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025018057/565938/Health-related-quality-of-life-after-second-line
08
早期鞘内注射地塞米松联合甲氨蝶呤可有效干预CAR-T细胞治疗相关免疫效应细胞神经毒性综合征
Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies
第一作者：Meng J
Front Immunol (IF=5.9). 2025 Dec 17;16:1716317.
全文网址：https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1716317/full
09
改良清淋方案能否提升高危大B细胞淋巴瘤患者接受Tisagenlecleucel的疗效？
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?
第一作者：Canelo-Vilaseca M
Bone Marrow Transplant (IF=5.2). 2026 Jan 8.
全文网址：https://www.nature.com/articles/s41409-025-02754-4
10
XPO1抑制剂联合CD19 CAR-T细胞在TP53突变弥漫大B细胞淋巴瘤治疗中的协同效应
Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL
第一作者：Bai Z
Tumori (IF=3.1). 2026 Jan 7:3008916251408273.
全文网址：https://journals.sagepub.com/doi/10.1177/03008916251408273
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2026.1-16 valid until 2028.1
供稿与审核：临床开发与医学部